Audentes Therapeutics (BOLD) Receives a Rating Update from a Top Analyst


In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Audentes Therapeutics (BOLD). The company’s shares closed yesterday at $37.21.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 51.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $42.57, a 14.4% upside from current levels. In a report issued on April 17, Leerink Partners also maintained a Buy rating on the stock with a $48 price target.

See today’s analyst top recommended stocks >>

Based on Audentes Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $35.59 million. In comparison, last year the company had a GAAP net loss of $25.57 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts